MX2023003052A - Formulaciones que comprenden alfa-glucosidasa acida recombinante. - Google Patents
Formulaciones que comprenden alfa-glucosidasa acida recombinante.Info
- Publication number
- MX2023003052A MX2023003052A MX2023003052A MX2023003052A MX2023003052A MX 2023003052 A MX2023003052 A MX 2023003052A MX 2023003052 A MX2023003052 A MX 2023003052A MX 2023003052 A MX2023003052 A MX 2023003052A MX 2023003052 A MX2023003052 A MX 2023003052A
- Authority
- MX
- Mexico
- Prior art keywords
- glucosidase
- recombinant acid
- formulations
- acid alpha
- mannose
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 title 1
- 108010028144 alpha-Glucosidases Proteins 0.000 title 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical group OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 241000699802 Cricetulus griseus Species 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 abstract 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 abstract 1
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 abstract 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 229960004593 alglucosidase alfa Drugs 0.000 abstract 1
- 201000004502 glycogen storage disease II Diseases 0.000 abstract 1
- 102000045921 human GAA Human genes 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Formulaciones farmacéuticas que comprenden una a-glucosidasa ácida recombinante, donde la a-glucosidasa ácida recombinante se expresa en células de ovario de hámster chino (CHO) y tiene un contenido de unidades de N-glicanos con uno o dos residuos de manosa-6-fosfato mayor que el contenido de unidades de N-glicanos con uno o dos residuos de manosa-6-fosfato de la alglucosidasa alfa; al menos un amortiguador seleccionado del grupo que consiste en el citrato, el fosfato y las combinaciones de éstos; y al menos un excipiente seleccionado del grupo que consiste en el manitol, el polisorbato 80 y las combinaciones de éstos, donde la formulación tiene un pH de entre aproximadamente 5.0 y aproximadamente 7.0. Métodos para tratar la enfermedad de Pompe donde se usan estas formulaciones farmacéuticas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662315436P | 2016-03-30 | 2016-03-30 | |
| US201762457588P | 2017-02-10 | 2017-02-10 | |
| US15/473,999 US10512676B2 (en) | 2016-03-30 | 2017-03-30 | Formulations comprising recombinant acid alpha-glucosidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003052A true MX2023003052A (es) | 2023-04-05 |
Family
ID=58632586
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003051A MX2023003051A (es) | 2016-03-30 | 2018-09-28 | Formulaciones que comprenden alfa-glucosidasa acida recombinante. |
| MX2023003052A MX2023003052A (es) | 2016-03-30 | 2018-09-28 | Formulaciones que comprenden alfa-glucosidasa acida recombinante. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003051A MX2023003051A (es) | 2016-03-30 | 2018-09-28 | Formulaciones que comprenden alfa-glucosidasa acida recombinante. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10512676B2 (es) |
| JP (3) | JP7510743B2 (es) |
| KR (4) | KR102758570B1 (es) |
| AU (2) | AU2017239641A1 (es) |
| BR (1) | BR112018069965A2 (es) |
| CA (1) | CA3019128A1 (es) |
| CL (1) | CL2018002768A1 (es) |
| CO (1) | CO2018011349A2 (es) |
| IL (4) | IL283430B (es) |
| MX (2) | MX2023003051A (es) |
| NZ (1) | NZ746713A (es) |
| SG (1) | SG11201808455VA (es) |
| WO (1) | WO2017173060A1 (es) |
| ZA (2) | ZA201807183B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102510941B1 (ko) | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| WO2017173060A1 (en) * | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
| DK3624831T5 (da) | 2017-05-15 | 2024-09-02 | Amicus Therapeutics Inc | Rekombinant human sur alfa-glucosidase |
| BR112019025888A2 (pt) | 2017-06-07 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica |
| JP7779653B2 (ja) | 2018-02-07 | 2025-12-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療用タンパク質送達のための方法および組成物 |
| MY206284A (en) | 2018-05-17 | 2024-12-06 | Regeneron Pharma | Anti-cd63 antibodies, conjugates, and uses thereof |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| SG11202111400TA (en) * | 2019-04-30 | 2021-11-29 | Univ Pennsylvania | Compositions useful for treatment of pompe disease |
| JP2022546587A (ja) | 2019-09-06 | 2022-11-04 | アミカス セラピューティックス インコーポレイテッド | 生物製剤の捕捉及び精製のための方法 |
| IL305103A (en) * | 2021-02-11 | 2023-10-01 | Amicus Therapeutics Inc | Recombinant human acid alpha-glucosidase and uses thereof |
| IL316776A (en) | 2022-05-05 | 2025-01-01 | Amicus Therapeutics Inc | Methods of treating Pompe disease |
| JP2025540135A (ja) | 2022-12-02 | 2025-12-11 | アミカス セラピューティックス インコーポレイテッド | 小児患者の乳児発症型ポンペ病の治療方法 |
| AR131256A1 (es) | 2022-12-02 | 2025-03-05 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de pompe de inicio tardío en pacientes pediátricos |
| WO2024151982A1 (en) * | 2023-01-13 | 2024-07-18 | Amicus Therapeutics, Inc. | Gene therapy constructs for the treatment of pompe disease |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837237A (en) | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
| US5879680A (en) | 1987-12-23 | 1999-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Cloned DNA for synthesizing unique glucocerebrosidase |
| US4985445A (en) | 1988-02-12 | 1991-01-15 | Meiji Seika Kaisha, Ltd. | Cancer cell metastasis inhibitors and novel compounds |
| US6451600B1 (en) | 1989-12-22 | 2002-09-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
| US5011829A (en) | 1989-06-02 | 1991-04-30 | G. D. Searle & Co. | Pharmaceutical composition and method of inhibiting virus |
| US5103008A (en) | 1989-08-17 | 1992-04-07 | Monsanto Company | Compound, N-butyl-deoxynojirimycin-6-phosphate |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| US20020073438A1 (en) * | 1995-08-02 | 2002-06-13 | Reuser Arnold J. | Methods of purifying human acid alpha-glucosidase |
| US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| US6210666B1 (en) | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
| ES2216327T3 (es) | 1997-11-10 | 2004-10-16 | G.D. SEARLE & CO. | Uso de iminoazucares alquilados para tratar la resistencia a multiples a farmacos. |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| AU3113700A (en) | 1998-12-07 | 2000-06-26 | Genzyme Corporation | Treatment of pompe's disease |
| ATE402701T1 (de) | 1999-02-12 | 2008-08-15 | United Therapeutics Corp | N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino- - glucitol zur behandlung von hepatitis-virus- infektionen |
| AU6050600A (en) | 1999-07-26 | 2001-02-13 | G.D. Searle & Co. | Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidaseenzyme for the manufacture of medicament for the treatment of glycolipid storag e diseases |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| ES2523024T3 (es) | 2000-07-18 | 2014-11-20 | Duke University | Tratamiento de glucogenosis de tipo II |
| CN1638739A (zh) | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
| US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| ATE384736T1 (de) | 2001-04-30 | 2008-02-15 | Zystor Therapeutics Inc | Subzelluläres targeting von therapeutischen proteinen |
| BR0213298A (pt) | 2001-10-16 | 2006-11-07 | Rxkinetix Inc | formulações com alta concentração de proteìna e processo de fabricação |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| WO2003086452A2 (en) | 2002-04-05 | 2003-10-23 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy |
| EP2444102B1 (en) | 2003-01-31 | 2015-04-08 | The Mount Sinai School of Medicine of New York University | Combination therapy for treating protein deficiency disorders |
| FR2861991B1 (fr) | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
| US20080014188A1 (en) | 2004-02-06 | 2008-01-17 | Zankel Todd C | Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof |
| JP4914224B2 (ja) | 2004-02-10 | 2012-04-11 | バイオマリン ファーマシューティカル インコーポレイテッド | 酸性αグルコシダーゼおよびそのフラグメント |
| US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| EP2932982B1 (en) | 2005-05-17 | 2018-10-03 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| MXPA05010977A (es) * | 2005-10-12 | 2007-04-11 | Abdala Leopoldo Espinosa | Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus. |
| WO2008063511A2 (en) | 2006-11-13 | 2008-05-29 | Zystor Therapeutics, Inc. | Methods for treating pompe disease |
| WO2008112525A2 (en) | 2007-03-09 | 2008-09-18 | Link Medicine Corporation | Treatment of lysosomal storage diseases |
| US9056101B2 (en) | 2007-04-26 | 2015-06-16 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2252288A1 (en) | 2007-11-21 | 2010-11-24 | Summit Corporation Plc | Treatment of protein folding disorders |
| WO2009075815A1 (en) | 2007-12-07 | 2009-06-18 | Duke University | Immunomodulating gene therapy |
| DK3470077T3 (da) | 2008-02-12 | 2020-11-30 | Amicus Therapeutics Inc | Fremgangsmåde til forudsigelse af respons på behandling af sygdomme med farmakologiske chaperoner |
| US20110136151A1 (en) | 2008-03-12 | 2011-06-09 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for pompe disease |
| AU2009223092A1 (en) | 2008-03-12 | 2009-09-17 | Amicus Therapeutics, Inc | Treatment of Pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers |
| US20110237538A1 (en) | 2008-08-06 | 2011-09-29 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| WO2010056746A1 (en) | 2008-11-11 | 2010-05-20 | Amicus Therapeutics, Inc. | Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease |
| HUE044381T2 (hu) | 2008-12-16 | 2019-10-28 | Genzyme Corp | Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállításához |
| JP5645918B2 (ja) | 2009-04-09 | 2014-12-24 | アミカス セラピューティックス インコーポレイテッド | リソソーム蓄積障害の予防および／または治療方法 |
| ES2569514T3 (es) | 2009-06-17 | 2016-05-11 | Biomarin Pharmaceutical Inc. | Formulaciones para enzimas lisosómicas |
| WO2011109600A1 (en) | 2010-03-05 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation pattern of a polypeptide |
| CA2833371A1 (en) | 2011-04-22 | 2012-10-26 | Genzyme Corporation | Modified acid alpha glucosidase with accelerated processing |
| WO2013013017A2 (en) | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
| BR112014014808A2 (pt) | 2011-12-22 | 2018-09-25 | Centogene Ip Gmbh | combinações de um composto que tem a capacidade de reorganizar uma enzima lisossômica e ambroxol e/ou um derivado de ambroxol, sua utilização, preparação farmacêutica e seu método de preparação |
| KR20230066482A (ko) | 2012-03-07 | 2023-05-15 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물 |
| EP2825193B1 (en) * | 2012-03-15 | 2019-11-13 | Oxyrane UK Limited | Methods and materials for treatment of pompe's disease |
| PT2844279T (pt) | 2012-05-03 | 2021-03-11 | Amicus Therapeutics Inc | Esquema posológico para o tratamento da doença de pompe |
| CA2915127A1 (en) | 2012-06-06 | 2013-12-12 | Giancarlo PARENTI | Allosteric chaperones and uses thereof |
| KR20250004926A (ko) | 2014-09-30 | 2025-01-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제 |
| KR102510941B1 (ko) * | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| KR102790256B1 (ko) * | 2016-03-30 | 2025-04-04 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 고 m6p 재조합 단백질의 선택 방법 |
| WO2017173060A1 (en) * | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
-
2017
- 2017-03-30 WO PCT/US2017/024982 patent/WO2017173060A1/en not_active Ceased
- 2017-03-30 KR KR1020237044402A patent/KR102758570B1/ko active Active
- 2017-03-30 NZ NZ746713A patent/NZ746713A/en unknown
- 2017-03-30 SG SG11201808455VA patent/SG11201808455VA/en unknown
- 2017-03-30 CA CA3019128A patent/CA3019128A1/en active Pending
- 2017-03-30 IL IL283430A patent/IL283430B/en unknown
- 2017-03-30 JP JP2018551370A patent/JP7510743B2/ja active Active
- 2017-03-30 KR KR1020187030850A patent/KR102444612B1/ko active Active
- 2017-03-30 IL IL301319A patent/IL301319A/en unknown
- 2017-03-30 BR BR112018069965A patent/BR112018069965A2/pt unknown
- 2017-03-30 KR KR1020257001831A patent/KR20250017756A/ko active Pending
- 2017-03-30 US US15/473,999 patent/US10512676B2/en active Active
- 2017-03-30 AU AU2017239641A patent/AU2017239641A1/en not_active Abandoned
- 2017-03-30 KR KR1020227031739A patent/KR102618519B1/ko active Active
-
2018
- 2018-09-27 IL IL261995A patent/IL261995B/en active IP Right Grant
- 2018-09-28 CL CL2018002768A patent/CL2018002768A1/es unknown
- 2018-09-28 MX MX2023003051A patent/MX2023003051A/es unknown
- 2018-09-28 MX MX2023003052A patent/MX2023003052A/es unknown
- 2018-10-24 CO CONC2018/0011349A patent/CO2018011349A2/es unknown
- 2018-10-26 ZA ZA2018/07183A patent/ZA201807183B/en unknown
-
2019
- 2019-10-16 US US16/654,521 patent/US11491211B2/en active Active
- 2019-10-22 ZA ZA2019/06938A patent/ZA201906938B/en unknown
-
2022
- 2022-04-07 JP JP2022063910A patent/JP2022105010A/ja not_active Withdrawn
- 2022-06-16 IL IL294012A patent/IL294012B2/en unknown
- 2022-11-07 US US18/053,151 patent/US20240066104A1/en active Pending
-
2024
- 2024-05-20 AU AU2024203333A patent/AU2024203333A1/en active Pending
- 2024-12-06 JP JP2024213793A patent/JP2025060645A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003051A (es) | Formulaciones que comprenden alfa-glucosidasa acida recombinante. | |
| MX2024015740A (es) | Alfa-glucosidasa acida humana recombinante | |
| NZ713967A (en) | Compositions and methods for treating gaucher disease | |
| MX2021004140A (es) | Celulas, isletas y organoides que evaden la deteccion inmunitaria y la autoinmunidad, metodos de produccion y usos de los mismos. | |
| MX2022014533A (es) | Metodo para seleccionar proteinas recombinantes ricas en m6p. | |
| HRP20191291T1 (hr) | Imunogeni pripravak | |
| WO2011154126A3 (en) | Skin antiaging treatment | |
| PE20141265A1 (es) | Formulaciones liofilizadas de fgf-18 | |
| BRPI0518793A2 (pt) | mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica | |
| WO2014165607A3 (en) | Aromatic-cationic peptide formulations, compositions and methods of use | |
| BR112012006283A2 (pt) | formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte | |
| BRPI0912411B8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune | |
| NZ600096A (en) | Formulations of antibody | |
| MX2017001898A (es) | Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales. | |
| MY187358A (en) | Modified release orally administered amino acid formulations | |
| MX2010013372A (es) | Dispositivo de liofilizacion a gran escala. | |
| AR068144A1 (es) | Administracion subcutanea de alfa-galactosidasa a | |
| PH12021551656A1 (en) | Pharmaceutical delivery compositions and uses thereof | |
| MX2019005466A (es) | Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia. | |
| MX2021000016A (es) | Formulaciones de factor de crecimiento de fibroblastos (fgf-21). | |
| EA201491369A1 (ru) | Способ лечения сахарного диабета при помощи негликозилированного аполипопротеина a-iv | |
| EA201391063A1 (ru) | Аполипопротеин a-iv в качестве антидиабетического пептида | |
| CY1125413T1 (el) | Φαρμακοτεχνικες μορφες αποτελουμενες απο ανασυνδυασμενη οξινη αλφα-γλυκοσιδαση | |
| WO2015061464A3 (en) | Recombinant glycoproteins and uses thereof | |
| MY210427A (en) | A method for the treatment or prophylaxis of cancer by targeting the extracellular portion of keratin 14 (krt14) residing on cancer cells |